Table 1.

Overview of data from trials exploring approved antiangiogenic mAbs plus EGFR-TKI combinations for the treatment of aNSCLC with activating EGFR mutations

Name of the trial (number of patients)	Phase of the trial	Experimental arm	Control arm	Efficacy data in months
BELIEF (n = 109)	II	Erlotinib + bevacizumab	/	mPFS: 13.2
JO25567 (n = 154)	II	Erlotinib + bevacizumab	Erlotinib	mPFS: 16.4 vs. 9.8 (HR: 0.54) mOS: 47.0 vs. 47.4 (HR: 0.81; P = 0.3267)
NEJ026 (n = 228)	III	Erlotinib + bevacizumab	Erlotinib	mPFS: 16.9 vs. 13.3 (HR: 0.60) mOS: 50.7 vs. 46.2 (HR: 1.007; P = 0.97)
BEVERLY (n = 160)	III	Erlotinib + bevacizumab	Erlotinib	mPFS: 15.4 vs. 9.7 (HR: 0.60) mOS: 28.4 vs. 23.0 (HR: 0.70; P = 0.12)
ARTEMIS-CTONG1509 (n = 311)	III	Erlotinib + bevacizumab	Erlotinib	mPFS: 17.9 vs. 11.2 (HR: 0.55) mOS: 36.2 vs. 31.6 (HR: 0.92; P = 0.581)
RELAY (n = 449)	III	Erlotinib + ramucirumab	Erlotinib	mPFS: 19.4 vs. 12.4 (HR: 0.59)

EGFR-TKI: Epidermal growth factor receptor-tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; HR: hazard ratio.